Literature DB >> 2527530

Effects of chronic heart failure on the responsiveness to angiotensin I and to angiotensin converting enzyme inhibition with cilazapril in rats.

J P Clozel1.   

Abstract

1. The effects of heart failure due to chronic myocardial infarction on the responsiveness to injected angiotensin I and ACE inhibition by intravenous cilazapril (1 mg kg-1) were evaluated. 2. For this purpose one group of 17 rats with a 4-week old myocardial infarction was compared with a group of 10 sham operated rats. 3. Heart failure increased markedly the responsiveness of the renal and mesenteric vascular beds to ACE inhibition which produced a vasodilation in these two vascular beds. 4. This increased responsiveness was most likely due to a stimulation of the renin-angiotensin system without any change of sensitivity to angiotensin I of the renal and mesenteric vascular beds. 5. Cilazapril produced the same level of ACE inhibition in both groups of rats.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2527530      PMCID: PMC1379744          DOI: 10.1111/j.1365-2125.1989.tb03478.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Effects of chronic therapy with cilazapril, a new angiotensin-converting enzyme inhibitor, on regional blood flows in conscious spontaneously hypertensive rats.

Authors:  J P Clozel; F Hefti
Journal:  J Cardiovasc Pharmacol       Date:  1987-09       Impact factor: 3.105

2.  Systemic and regional hemodynamic effects of captopril and milrinone administered alone and concomitantly in patients with heart failure.

Authors:  T H LeJemtel; C S Maskin; D Mancini; L Sinoway; H Feld; B Chadwick
Journal:  Circulation       Date:  1985-08       Impact factor: 29.690

3.  Effects of captopril and enalapril on regional vascular resistance and reactivity in spontaneously hypertensive rats.

Authors:  C Richer; M P Doussau; J F Giudicelli
Journal:  Hypertension       Date:  1983 May-Jun       Impact factor: 10.190

4.  Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure.

Authors:  M A Creager; J L Halperin; D B Bernard; D P Faxon; C D Melidossian; H Gavras; T J Ryan
Journal:  Circulation       Date:  1981-09       Impact factor: 29.690

5.  Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system.

Authors:  M Packer; W H Lee; P D Kessler
Journal:  Circulation       Date:  1986-10       Impact factor: 29.690

6.  Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril.

Authors:  M A Pfeffer; J M Pfeffer; C Steinberg; P Finn
Journal:  Circulation       Date:  1985-08       Impact factor: 29.690

7.  Biological properties of the angiotensin-converting enzyme inhibitor cilazapril.

Authors:  I L Natoff; J S Nixon; R J Francis; L R Klevans; M Brewster; J Budd; A T Patel; J Wenger; E Worth
Journal:  J Cardiovasc Pharmacol       Date:  1985 May-Jun       Impact factor: 3.105

8.  Effects of chronic myocardial infarction on responsiveness to isoprenaline and the state of myocardial beta adrenoceptors in rats.

Authors:  J P Clozel; M Holck; W Osterrieder; W Burkard; M D Da Prada
Journal:  Cardiovasc Res       Date:  1987-09       Impact factor: 10.787

9.  New potent inhibitors of angiotensin converting enzyme.

Authors:  M R Attwood; R J Francis; C H Hassall; A Kröhn; G Lawton; I L Natoff; J S Nixon; S Redshaw; W A Thomas
Journal:  FEBS Lett       Date:  1984-01-09       Impact factor: 4.124

10.  Regional blood flow measurement with pulsed Doppler flowmeter in conscious rat.

Authors:  J R Haywood; R A Shaffer; C Fastenow; G D Fink; M J Brody
Journal:  Am J Physiol       Date:  1981-08
View more
  1 in total

Review 1.  Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.

Authors:  F Deget; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.